{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T14:19:11Z","timestamp":1794838751652,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:00:00Z","timestamp":1794787200000},"content-version":"vor","delay-in-days":142,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"DOI":"10.1038\/s41523-026-01001-3","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:57:55Z","timestamp":1782712675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Wanbing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2387-6676","authenticated-orcid":false,"given":"Benyam","family":"Muluneh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-5805","authenticated-orcid":false,"given":"Jim H.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-4796","authenticated-orcid":false,"given":"Lynne I.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-2543","authenticated-orcid":false,"given":"William A.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3813-9318","authenticated-orcid":false,"given":"Ethan","family":"Basch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3317-0311","authenticated-orcid":false,"given":"Jiawei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1001_CR1","volume":"6","author":"A Pulumati","year":"2023","unstructured":"Pulumati, A., Pulumati, A., Dwarakanath, B. S., Verma, A. & Papineni, R. V. L. Technological advancements in cancer diagnostics: improvements and limitations. Cancer Rep. 6, e1764 (2023).","journal-title":"Cancer Rep."},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1200\/JCO.23.02475","volume":"42","author":"BE Wilson","year":"2024","unstructured":"Wilson, B. E., Wright, K., Koven, R. & Booth, C. M. Surveillance imaging after curative-intent treatment for cancer: benefits, harms, and evidence. J. Clin. Oncol. 42, 2245\u20132249 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1474-4422(19)30357-6","volume":"18","author":"A Khajuria","year":"2019","unstructured":"Khajuria, A. Patient-reported outcomes in the spotlight. Lancet Neurol. 18, 981 (2019).","journal-title":"Lancet Neurol."},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","volume":"13","author":"M Di Maio","year":"2016","unstructured":"Di Maio, M., Basch, E., Bryce, J. & Perrone, F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat. Rev. Clin. Oncol. 13, 319\u2013325 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrclinonc.2017.153","volume":"14","author":"TW LeBlanc","year":"2017","unstructured":"LeBlanc, T. W. & Abernethy, A. P. Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat. Rev. Clin. Oncol. 14, 763\u2013772 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S1470-2045(18)30141-4","volume":"19","author":"E Basch","year":"2018","unstructured":"Basch, E. Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncol. 19, 595\u2013597 (2018).","journal-title":"Lancet Oncol."},{"key":"1001_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102838","volume":"76","author":"C Yap","year":"2024","unstructured":"Yap, C. et al. Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable. EClinicalMedicine 76, 102838 (2024).","journal-title":"EClinicalMedicine"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jamaoncol.2022.0864","volume":"8","author":"JN Samuel","year":"2022","unstructured":"Samuel, J. N. et al. Association of quality-of-life outcomes in cancer drug trials with survival outcomes and drug class. JAMA Oncol. 8, 879\u2013886 (2022).","journal-title":"JAMA Oncol."},{"key":"1001_CR9","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/onco.13806","volume":"26","author":"S Badaoui","year":"2021","unstructured":"Badaoui, S., Kichenadasse, G., Rowland, A., Sorich, M. J. & Hopkins, A. M. Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with Abemaciclib. Oncologist 26, 562\u2013568 (2021).","journal-title":"Oncologist"},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1158\/1078-0432.CCR-25-0292","volume":"31","author":"J Zhou","year":"2025","unstructured":"Zhou, J., Muluneh, B., Wang, Z., Yao, H. & Hughes, J. H. Leveraging longitudinal patient-reported outcome trajectories to predict survival in non-small cell lung cancer. Clin. Cancer Res. 31, 2685\u20132694 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1001_CR11","first-page":"S574","volume":"8","author":"MH Frost","year":"2002","unstructured":"Frost, M. H. & Sloan, J. A. Quality of life measurements: a soft outcome-or is it? Am. J. Manag. Care 8, S574\u2013S579 (2002).","journal-title":"Am. J. Manag. Care"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.5435\/JAAOS-D-23-00040","volume":"31","author":"EC Makhni","year":"2023","unstructured":"Makhni, E. C. & Hennekes, M. E. The use of patient-reported outcome measures in clinical practice and clinical decision making. J. Am. Acad. Orthop. Surg. 31, 1059\u20131066 (2023).","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/0959-8049(95)00296-0","volume":"31a","author":"S Kaasa","year":"1995","unstructured":"Kaasa, S. et al. The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy. Eur. J. Cancer 31a, 2260\u20132263 (1995).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00774-022-01382-y","volume":"41","author":"D Takei","year":"2023","unstructured":"Takei, D. & Tagami, K. Management of cancer pain due to bone metastasis. J. Bone Min. Metab. 41, 327\u2013336 (2023).","journal-title":"J. Bone Min. Metab."},{"key":"1001_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR16","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1158\/2159-8290.CD-25-0293","volume":"15","author":"K Koh","year":"2025","unstructured":"Koh, K. et al. Cancer-associated cachexia: bridging clinical findings with mechanistic insights in human studies. Cancer Discov. 15, 1543\u20131568 (2025).","journal-title":"Cancer Discov."},{"key":"1001_CR17","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland, E. J. et al. Management of cancer cachexia: ASCO guideline. J. Clin. Oncol. 38, 2438\u20132453 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s12276-022-00752-w","volume":"54","author":"E Yeom","year":"2022","unstructured":"Yeom, E. & Yu, K. Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Exp. Mol. Med. 54, 426\u2013432 (2022).","journal-title":"Exp. Mol. Med."},{"key":"1001_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s00520-023-08274-5","volume":"32","author":"D Arcos","year":"2024","unstructured":"Arcos, D., Ng, D. Q., Ke, Y., Toh, Y. L. & Chan, A. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy. Support Care Cancer 32, 76 (2024).","journal-title":"Support Care Cancer"},{"key":"1001_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/NCC.0000000000000976","volume":"45","author":"KP Singh","year":"2022","unstructured":"Singh, K. P. et al. Multiple gastrointestinal symptoms are associated with chemotherapy-induced nausea in patients with breast cancer. Cancer Nurs. 45, 181\u2013189 (2022).","journal-title":"Cancer Nurs."},{"key":"1001_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2023.1182488","volume":"4","author":"LV Doan","year":"2023","unstructured":"Doan, L. V., Yoon, J., Chun, J., Perez, R. & Wang, J. Pain associated with breast cancer: etiologies and therapies. Front. Pain. Res. 4, 1182488 (2023).","journal-title":"Front. Pain. Res."},{"key":"1001_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103153","volume":"82","author":"L Lim","year":"2025","unstructured":"Lim, L. et al. Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study. EClinicalMedicine 82, 103153 (2025).","journal-title":"EClinicalMedicine"},{"key":"1001_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","volume":"10","author":"C Quinten","year":"2009","unstructured":"Quinten, C. et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 10, 865\u2013871 (2009).","journal-title":"Lancet Oncol."},{"key":"1001_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar, W. J. et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 22, 331\u2013357 (2024).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"1001_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s41687-024-00808-7","volume":"8","author":"D Krepper","year":"2024","unstructured":"Krepper, D., Cesari, M., Hubel, N. J., Zelger, P. & Sztankay, M. J. Machine learning models including patient-reported outcome data in oncology: a systematic literature review and analysis of their reporting quality. J. Patient Rep. Outcomes 8, 126 (2024).","journal-title":"J. Patient Rep. Outcomes"},{"key":"1001_CR26","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","volume":"97","author":"S Siena","year":"2007","unstructured":"Siena, S. et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br. J. Cancer 97, 1469\u20131474 (2007).","journal-title":"Br. J. Cancer"},{"key":"1001_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14724-6","volume":"25","author":"M Kort\u00fcm","year":"2025","unstructured":"Kort\u00fcm, M. et al. Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data. BMC Cancer 25, 1288 (2025).","journal-title":"BMC Cancer"},{"key":"1001_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jamaoncol.2024.6157","volume":"11","author":"JA Colbert","year":"2025","unstructured":"Colbert, J. A. & Potters, L. Overcoming barriers to make patient-reported outcome collection the standard of care in oncology. JAMA Oncol. 11, 233\u2013234 (2025).","journal-title":"JAMA Oncol."},{"key":"1001_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11764-021-01135-2","volume":"16","author":"C Mazariego","year":"2022","unstructured":"Mazariego, C. et al. Priority recommendations for the implementation of patient-reported outcomes in clinical cancer care: a Delphi study. J. Cancer Surviv. 16, 33\u201343 (2022).","journal-title":"J. Cancer Surviv."},{"key":"1001_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.13063\/2327-9214.1169","volume":"3","author":"A Stover","year":"2015","unstructured":"Stover, A. et al. Integrating patient-reported outcome measures into routine cancer care: cancer patients\u2019 and clinicians\u2019 perceptions of acceptability and value. EGEMS 3, 1169 (2015).","journal-title":"EGEMS"},{"key":"1001_CR31","first-page":"123","volume":"24","author":"S Bellino","year":"2024","unstructured":"Bellino, S. & La Salvia, A. The importance of patient reported outcomes in oncology clinical trials and clinical practice to inform regulatory and healthcare decision-making. Drugs 24, 123\u2013127 (2024).","journal-title":"Drugs"},{"key":"1001_CR32","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/1078-0432.CCR-24-4073","volume":"31","author":"J Zhou","year":"2025","unstructured":"Zhou, J., Muluneh, B., Li, Q. & Hughes, J. H. Revolutionizing patient-reported outcomes analysis for oncology drug development using population models. Clin. Cancer Res. 31, 1580\u20131586 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1001_CR33","doi-asserted-by":"crossref","unstructured":"Zou, Y., Sun, Y., Ravva, S., Wagner, L. I. & Zhou, J. A model-based meta-analysis of pembrolizumab effects on patient-reported quality of life: advancing patient-centered oncology drug development. CPT Pharmacomet. Syst. Pharmacol. 15, e70106 (2026).","DOI":"10.1002\/psp4.70106"},{"key":"1001_CR34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2023.04.027","volume":"188","author":"JZ Musoro","year":"2023","unstructured":"Musoro, J. Z. et al. Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: a synthesis across 21 clinical trials involving nine different cancer types. Eur. J. Cancer 188, 171\u2013182 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jval.2023.12.012","volume":"27","author":"NA Clarke","year":"2024","unstructured":"Clarke, N. A. et al. A review of meaningful change thresholds for EORTC QLQ-C30 and FACT-G within oncology. Value Health 27, 458\u2013468 (2024).","journal-title":"Value Health"},{"key":"1001_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey, J. R. et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 14, 72\u201380 (2013).","journal-title":"Lancet Oncol."},{"key":"1001_CR37","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/annonc\/mdw098","volume":"27","author":"JR Mackey","year":"2016","unstructured":"Mackey, J. R. et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann. Oncol. 27, 1041\u20131047 (2016).","journal-title":"Ann. Oncol."},{"key":"1001_CR38","unstructured":"Fayers, P. et al. EORTC QLQ-C30 scoring manual. European Organisation for Research and Treatment of Cancer, Brussels, URL: https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf (2001)."},{"key":"1001_CR39","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K. et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365\u2013376 (1993).","journal-title":"J. Natl. Cancer Inst."},{"key":"1001_CR40","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers, P. & Bottomley, A. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur. J. Cancer 38, S125\u2013S133 (2002).","journal-title":"Eur. J. Cancer"},{"key":"1001_CR41","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s11136-006-0040-x","volume":"15","author":"NW Scott","year":"2006","unstructured":"Scott, N. W. et al. Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses. Qual. Life Res. 15, 1103\u20131115 (2006).","journal-title":"Qual. Life Res."},{"key":"1001_CR42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s41687-024-00824-7","volume":"8","author":"K Cocks","year":"2024","unstructured":"Cocks, K. et al. Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations. J. Patient Rep. Outcomes 8, 150 (2024).","journal-title":"J. Patient Rep. Outcomes"},{"key":"1001_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139\u2013144 (1998).","journal-title":"J. Clin. Oncol."},{"key":"1001_CR44","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"1001_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould, D. R. & Upton, R. N. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacomet. Syst. Pharm. 1, e6 (2012).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"1001_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36121-y","volume":"14","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Mapping lesion-specific response and progression dynamics and inter-organ variability in metastatic colorectal cancer. Nat. Commun. 14, 417 (2023).","journal-title":"Nat. Commun."},{"key":"1001_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/0008-5472.CAN-19-1940","volume":"80","author":"J Zhou","year":"2020","unstructured":"Zhou, J., Liu, Y., Zhang, Y., Li, Q. & Cao, Y. Modeling tumor evolutionary dynamics to predict clinical outcomes for patients with metastatic colorectal cancer: a retrospective analysis. Cancer Res. 80, 591\u2013601 (2020).","journal-title":"Cancer Res."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01001-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T13:38:08Z","timestamp":1794836288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-026-01001-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1038\/s41523-026-01001-3","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.M. may own stock in Novartis. J.H.H. is a current employee of Pfizer and may own stock in Pfizer. L.I.W. receives institutional research funding from the National Cancer Institute and previously received personal fees from Celgene\/Bristol Myers Squibb as a member of the Scientific Steering Committee for the Connect Multiple Myeloma patient registry. W.A.W. has received institutional research funding from Genentech; receives consulting fees from Teladoc Health, Quantum Health, and Lantern Health; holds equity in Koneksa Health; and has a leadership position in the American Society of Hematology Research Collaborative. E.B. receives institutional research funding from the National Cancer Institute and from the Patient-Centered Outcomes Research Institute, and personal fees for scientific advising from Research Triangle Institute, Thyme Care, N-Power Medicine, Resilience Health, Canopy Care, Savor Health, and Navigating Cancer. The other authors do not have a competing interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"148"}}